Stories

OHSU receives $8 million NIH grant to strengthen defenses against future pandemics

By Angela Yeager October 27, 2026

Federal investment supports a state-of-the-art Biosafety Level 3 laboratory for studying emerging infectious diseases.

OHSU recibe una subvención de $8 millones de los NIH para fortalecer las defensas contra pandemias futuras

By Angela Yeager October 27, 2026

La inversión federal respalda un laboratorio de bioseg.uridad nivel 3 de vanguardia para estudiar enfermedades infecciosas emergentes

Investigadores(as) de OHSU obtienen $12.5 millones para estudiar la ubiquitina, una molécula fundamental en la salud y la enfermedad

By Angela Yeager October 14, 2026

Uno de los sistemas de señalización celular más importantes en la biología reúne a investigadores de OHSU de distintas especialidades, como enfermedades infecciosas, inmunología, neurociencias, biología del cáncer y gastroenterología.

OHSU researchers secure $12.5 million to explore ubiquitin, a fundamental driver of health, disease

By Angela Yeager October 14, 2026

One of biology’s most important cellular signaling systems unite OHSU scientists across infectious disease, immunology, neuroscience, cancer biology, gastroenterology.

OHSU recibe $7.5 millones para impulsar la terapia génica contra las enfermedades renales

By Angela Yeager October 08, 2026

El laboratorio Nakai recibe tres subvenciones de los NIH para desarrollar posibles tratamientos curativos para enfermedades renales hereditarias.

OHSU awarded $7.5 million to advance gene therapy for kidney diseases

By Angela Yeager October 08, 2026

Nakai lab receives three NIH grants to develop potential curative treatments for inherited kidney diseases.

OHSU secures $4.6 million to expand clinical trials in underserved rural communities

By Angela Yeager September 30, 2026

New CARE for Health™ awards will bring maternal health, chronic pain studies to rural clinics across the Northwest.

Intermittent fasting shows promise in slowing Huntington’s disease progression

By Angela Yeager September 17, 2026

OHSU-led pilot study finds time-restricted eating is feasible, safe, linked to improvements in disease markers.

Cancer cells use antioxidant protein to suppress T cells, resist immunotherapy, study finds

By Angela Yeager September 03, 2026

OHSU co-author helps identify potential therapeutic target in tumors that evade the immune system.

Las células cancerosas utilizan una proteína antioxidante para suprimir las células T y resistir la inmunoterapia, según un estudio

By Angela Yeager September 03, 2026

Un coautor de OHSU ayuda a identificar una posible diana terapéutica en tumores que eluden el sistema inmunitario.

Author: Angela Yeager

OHSU in the News